ClinicalTrials.gov
ClinicalTrials.gov Menu

A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01076517
Recruitment Status : Available
First Posted : February 26, 2010
Last Update Posted : April 18, 2018
Sponsor:
Collaborator:
BTG International Inc.
Information provided by (Responsible Party):
Daniel Yung-Ho Sze, Stanford University

February 24, 2010
February 26, 2010
April 18, 2018
 
A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma
To provide Therasphere treatment for patients diagnosed with unresectable liver cancer.
Not Provided
Expanded Access
Device: Therasphere
Beta-emitting 90yttrium encapsulated in glass microspheres for intraarterial administration to the liver.
Other Names:
  • HCC
  • hepatocellular carcinoma treatment
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Available
Contact: Danielle Katz 650-723-0728 dkatz@stanfordhealthcare.org
United States
 
 
NCT01076517
Daniel Yung-Ho Sze, Stanford University
Stanford University
BTG International Inc.
Principal Investigator: Daniel Yung-Ho Sze Stanford University
Stanford University
April 2018